



Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer

March 1, 2011

SYNDAX ANNOUNCES START OF NCI SPONSORED PHASE 2 STUDY OF ENTINOSTAT IN COMBINATION IN TRIPLE NEGATIVE BREAST CANCER